JAZZ - Jazz Pharmaceuticals plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
129.00
-1.82 (-1.39%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close130.82
Open131.29
Bid128.88 x 1000
Ask134.00 x 900
Day's Range128.52 - 131.75
52 Week Range113.52 - 173.10
Volume327,960
Avg. Volume462,840
Market Cap7.548B
Beta (3Y Monthly)0.99
PE Ratio (TTM)11.70
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • PR Newswire

    Jazz Pharmaceuticals Announces Acquisition of Cavion, Inc.

    Transaction Adds Worldwide Rights to CX-8998, a Modulator of T-type Calcium Channels, for the Potential Treatment of Essential Tremor Strong Strategic Fit with a Differentiated Mechanism of Action in an ...

  • PR Newswire

    Jazz Pharmaceuticals Announces Second Quarter 2019 Financial Results

    Total Revenues Increased 7% to $534 Million GAAP Diluted EPS of $4.56 ; Adjusted Diluted EPS of $4.05 Launched Sunosi in Early July in the U.S. Expansion of Defitelio into Japan Following Nippon Shinyaku ...

  • PR Newswire

    Jazz Pharmaceuticals Advances Recombinant Crisantaspase Development Program

    DUBLIN, Aug. 6, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the Phase 1 study of its recombinant crisantaspase molecule, JZP-458, met its efficacy and safety objectives. The company plans to initiate a single-arm, pivotal Phase 2/3 study evaluating JZP-458 as a potential treatment option for patients with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) who are hypersensitive to E. coli-derived asparaginase products. "Jazz is committed to the ALL patient community, and we are pleased to advance this development program with the goal of bringing a new treatment option to ALL and LBL patients who are hypersensitive to E. coli-derived asparaginase products as soon as possible," said Robert Iannone, M.D., M.S.C.E., executive vice president, research and development of Jazz Pharmaceuticals.

  • PR Newswire

    Jazz Pharmaceuticals to Report 2019 Second Quarter Financial Results on August 6, 2019

    DUBLIN , July 23, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 second quarter financial results on Tuesday, August 6, 2019 , after the close ...

  • PR Newswire

    Jazz Pharmaceuticals Acquires Pre-clinical Pan-RAF Inhibitor Program from Redx Pharma

    Pan-RAF Program adds an Early Stage, Innovative, Precision Oncology Asset to Jazz Pharmaceuticals' Growing R&D Portfolio Redx to Receive $3.5 Million Upfront, up to $203 Million in Milestone Payments and ...

  • PR Newswire

    Jazz Pharmaceuticals Announces Webcast for Sunosi Investor Update

    DUBLIN, June 25, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the company will host a webcast on Tuesday, July 2, 2019 at 4:30 p.m. EDT/9:30 p.m. IST to provide investors with an update on Sunosi™ (solriamfetol), which was approved by the U.S. Food and Drug Administration on March 20, 2019 to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).  Sunosi is the first dual-acting dopamine and norepinephrine reuptake inhibitor approved to treat excessive daytime sleepiness in adults living with narcolepsy or OSA.  Beginning early July, Sunosi will be commercially available in the U.S. following the recent scheduling decision by the U.S. Drug Enforcement Agency. A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.  Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

  • PR Newswire

    Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi™ (solriamfetol)

    DUBLIN, June 17, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the U.S. Drug Enforcement Agency (DEA) has designated solriamfetol, also known as Sunosi, as a Schedule IV medicine. With U.S. Food and Drug Administration (FDA) approval on March 20, 2019, Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) approved to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).

  • PR Newswire

    Jazz Pharmaceuticals Appoints Dr. Robert Iannone as Executive Vice President, Research and Development

    DUBLIN, June 3, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced the appointment of Robert Iannone, M.D., M.S.C.E., as executive vice president, research and development, effective May 29, 2019. Dr. Iannone will lead Jazz's growing global R&D organization, including the pre-clinical development, clinical development, clinical operations, biostatistics, medical affairs, regulatory affairs, pharmacovigilance and safety functions. "Rob's extensive industry knowledge, leadership experience and strategic insights bring expertise in areas critical to our expanding capabilities as an innovative, global biopharmaceutical company with growing R&D investment and portfolio," said Daniel Swisher, president and chief operating officer at Jazz Pharmaceuticals.

  • PR Newswire

    Jazz Pharmaceuticals to Present New Data at Upcoming ASCO Annual Meeting and EHA Congress

    Data to be presented underscore commitment to developing life-changing medicines in hematology/oncology for people with limited or no treatment options DUBLIN , May 16, 2019 /PRNewswire/ -- Jazz Pharmaceuticals ...

  • PR Newswire

    Jazz Pharmaceuticals Data to Showcase Ongoing Sleep Medicine Research at SLEEP 2019

    Fourteen abstracts highlight Jazz's breadth in sleep medicine research and commitment to developing treatment options for people living with debilitating sleep disorders DUBLIN , May 9, 2019 /PRNewswire/ ...

  • PR Newswire

    Jazz Pharmaceuticals Announces First Quarter 2019 Financial Results

    Total Revenues Increased 14% to $508 Million GAAP Diluted EPS of $1.47 ; Adjusted Diluted EPS of $3.67 Received FDA Approval of Sunosi for Excessive Daytime Sleepiness (EDS) Associated with Narcolepsy ...

  • PR Newswire

    Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences

    DUBLIN, May 6, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences. Dan Swisher, president and chief operating officer, will provide an overview of the company and a business and financial update. A live audio webcast of each presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.  Please connect to the website prior to the start of each presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

  • PR Newswire

    Jazz Pharmaceuticals to Report 2019 First Quarter Financial Results on May 7, 2019

    DUBLIN , April 23, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 first quarter financial results on Tuesday, May 7, 2019 , after the close of ...

  • PR Newswire

    Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness

    DUBLIN, March 26, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced positive top-line results from the global, double-blind, placebo-controlled, randomized-withdrawal, multicenter Phase 3 study evaluating the efficacy and safety of JZP-258 for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult patients with narcolepsy. JZP-258 is a novel oxybate product candidate with a unique composition of cations resulting in 92% less sodium than Xyrem® (sodium oxybate).

  • PR Newswire

    Jazz Pharmaceuticals Announces U.S. FDA Approval of Sunosi™ (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

    DUBLIN, March 20, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Sunosi™ (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA). Once-daily Sunosi is approved with doses of 75 mg and 150 mg for patients with narcolepsy and doses of 37.5 mg, 75 mg, and 150 mg for patients with OSA.

  • PR Newswire

    Jazz Pharmaceuticals to Present at the Cowen and Company 39th Annual Healthcare Conference

    DUBLIN, March 5, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the company will be webcasting its corporate presentation at the Cowen and Company 39th Annual Healthcare Conference in Boston, MA. A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.  Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. An archive of the webcast will be available for at least one week following the presentation on the Investors section of the company's website at www.jazzpharmaceuticals.com.

  • PR Newswire

    Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2018 Financial Results

    Total Revenues Increased 17% to $1.9 Billion in 2018 GAAP Diluted EPS of $7.30 ; Adjusted Diluted EPS of $13.70 Launched Vyxeos for AML in the EU and Initiated Broad Development Program Received U.S. Approval ...

  • ACCESSWIRE

    Jazz Pharmaceuticals Plc to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 26, 2019 / Jazz Pharmaceuticals Plc (NASDAQ: JAZZ ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 26, 2019 ...

  • GlobeNewswire

    New Research: Key Drivers of Growth for IPG Photonics, Keane Group, Jazz Pharmaceuticals, Tredegar, Carriage Services, and Surgery Partners — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Feb. 15, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • PR Newswire

    Jazz Pharmaceuticals Announces Appointment of Anne O'Riordan to its Board of Directors

    DUBLIN , Feb. 14, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Anne O'Riordan , Senior Managing Director, Life Sciences of Accenture, was appointed to its Board of ...

  • PR Newswire

    Jazz Pharmaceuticals to Report 2018 Fourth Quarter and Full Year Financial Results on February 26, 2019

    DUBLIN , Feb. 12, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2018 fourth quarter and full year financial results on Tuesday, February 26, 2019 ...

  • PR Newswire

    Jazz Pharmaceuticals and Codiak BioSciences Announce Strategic Collaboration to Research, Develop and Commercialize Engineered Exosomes to Create Therapies for Hard-to-Treat Cancers

    DUBLIN and CAMBRIDGE, Mass., Jan. 3, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) and Codiak BioSciences, Inc. today announced that the companies have entered into a strategic collaboration agreement focused on the research, development and commercialization of exosome therapeutics to treat cancer. Codiak granted Jazz an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize therapeutic candidates directed at five targets to be developed using Codiak's engEx™ precision engineering platform for exosome therapeutics.

  • PR Newswire

    Jazz Pharmaceuticals Receives New PDUFA Goal Date for Solriamfetol for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

    DUBLIN, Dec. 21, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for its new drug application (NDA) for solriamfetol as a treatment to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA). The FDA determined that an NDA submission made by Jazz during the course of discussions regarding draft labeling for solriamfetol constitutes a major amendment to the NDA, resulting in a three-month extension of the PDUFA goal date to provide time for a full review of the submission.

  • PR Newswire

    Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 7

    DUBLIN, Dec. 19, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the company will be webcasting its corporate presentation at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at http://www.jazzpharmaceuticals.com.  Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. An archive of the webcast will be available for at least one week following the presentation on the Investors section of the company's website at http://www.jazzpharmaceuticals.com.

  • PR Newswire

    Jazz Pharmaceuticals Announces Share Repurchase Program Authorization Increase of $400 Million

    DUBLIN, Dec. 10, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that its Board of Directors has authorized a $400 million increase in the company's share repurchase program, which the company intends to use over time based on market conditions and other factors. Prior to this increased authorization, the Board of Directors had authorized $620 million under the company's share repurchase program, of which $194 million had been utilized through September 30, 2018.  Since that date, the company has utilized the remainder of that prior authorization.